You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR SIKLOS


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SIKLOS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01976416 ↗ Novel Use Of Hydroxyurea in an African Region With Malaria Completed Children's Hospital Medical Center, Cincinnati Phase 3 2014-09-01 Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan Africa, the areas with the most children with SCA. The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for children with SCA in a malaria endemic region within sub-Saharan Africa.
NCT01976416 ↗ Novel Use Of Hydroxyurea in an African Region With Malaria Completed Doris Duke Charitable Foundation Phase 3 2014-09-01 Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan Africa, the areas with the most children with SCA. The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for children with SCA in a malaria endemic region within sub-Saharan Africa.
NCT01976416 ↗ Novel Use Of Hydroxyurea in an African Region With Malaria Completed Makerere University Phase 3 2014-09-01 Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan Africa, the areas with the most children with SCA. The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for children with SCA in a malaria endemic region within sub-Saharan Africa.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SIKLOS

Condition Name

Condition Name for SIKLOS
Intervention Trials
Sickle Cell Disease 7
Malaria 2
Sickle Cell Anemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SIKLOS
Intervention Trials
Anemia, Sickle Cell 8
Anemia 2
Malaria 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SIKLOS

Trials by Country

Trials by Country for SIKLOS
Location Trials
France 7
Uganda 3
Italy 1
French Guiana 1
Guadeloupe 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SIKLOS
Location Trials
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SIKLOS

Clinical Trial Phase

Clinical Trial Phase for SIKLOS
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SIKLOS
Clinical Trial Phase Trials
Completed 6
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SIKLOS

Sponsor Name

Sponsor Name for SIKLOS
Sponsor Trials
ADDMEDICA SASA 5
Mulago Hospital, Uganda 3
Children's Hospital Medical Center, Cincinnati 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SIKLOS
Sponsor Trials
Other 21
Industry 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.